MINERALYS THERAPEUTICS, INC. Research and Development Expense
MINERALYS THERAPEUTICS, INC. (MLYS) reported Research and Development Expense of $221.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $221.38M, a 478.34% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $24.36M, a 35.68% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $24.40M, a 45.25% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $31.45M, a 41.74% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. research and development expense for fiscal 2025 was $132.01M, a 21.69% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. research and development expense for fiscal 2024 was $168.58M, a 139.59% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. research and development expense for fiscal 2023 was $70.36M, a 168.04% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. research and development expense for fiscal 2022 was $26.25M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $221.38M 10-Q · filed 2026-08-11 | $245.74M 10-Q · filed 2026-08-11 | $270.14M derived: sum of 3 quarters · filed 2026-08-11 | $301.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $24.36M 10-Q · filed 2026-05-06 | $48.77M derived: sum of 2 quarters · filed 2026-05-06 | $80.22M derived: sum of 3 quarters · filed 2026-05-06 | $118.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $24.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $55.85M derived: sum of 2 quarters · filed 2026-03-12 | $94.13M derived: sum of 3 quarters · filed 2026-08-11 | $132.01M 10-K · filed 2026-03-12 |
| 2025-09-30 | $31.45M 10-Q · filed 2025-11-10 | $69.73M derived: sum of 2 quarters · filed 2026-08-11 | $107.61M 10-Q · filed 2025-11-10 | $152.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $38.28M 10-Q · filed 2026-08-11 | $76.16M 10-Q · filed 2026-08-11 | $120.73M derived: sum of 3 quarters · filed 2026-08-11 | $174.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $37.88M 10-Q · filed 2026-05-06 | $82.45M derived: sum of 2 quarters · filed 2026-05-06 | $136.43M derived: sum of 3 quarters · filed 2026-05-06 | $175.71M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $44.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $98.55M derived: sum of 2 quarters · filed 2026-03-12 | $137.83M derived: sum of 3 quarters · filed 2026-03-12 | $168.58M 10-K · filed 2026-03-12 |
| 2024-09-30 | $53.98M 10-Q · filed 2025-11-10 | $93.26M derived: sum of 2 quarters · filed 2025-11-10 | $124.01M 10-Q · filed 2025-11-10 | $147.70M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $39.27M 10-Q · filed 2025-08-12 | $70.03M 10-Q · filed 2025-08-12 | $93.71M derived: sum of 3 quarters · filed 2025-08-12 | $116.21M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $30.75M 10-Q · filed 2025-05-12 | $54.44M derived: sum of 2 quarters · filed 2025-05-12 | $76.94M derived: sum of 3 quarters · filed 2025-05-12 | $88.82M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $23.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $46.18M derived: sum of 2 quarters · filed 2025-02-12 | $58.07M derived: sum of 3 quarters · filed 2025-02-12 | $70.36M 10-K · filed 2025-02-12 |
| 2023-09-30 | $22.50M 10-Q · filed 2024-11-12 | $34.38M derived: sum of 2 quarters · filed 2024-11-12 | $46.68M 10-Q · filed 2024-11-12 | $54.49M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $11.88M 10-Q · filed 2024-08-13 | $24.18M 10-Q · filed 2024-08-13 | $32.00M derived: sum of 3 quarters · filed 2024-08-13 | $38.05M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $12.29M 10-Q · filed 2024-05-09 | $20.11M derived: sum of 2 quarters · filed 2024-05-09 | $26.17M derived: sum of 3 quarters · filed 2024-05-09 | $31.77M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $7.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $13.88M derived: sum of 2 quarters · filed 2024-03-21 | $19.47M derived: sum of 3 quarters · filed 2024-03-21 | $26.25M 10-K · filed 2024-03-21 |
| 2022-09-30 | $6.06M 10-Q · filed 2023-11-07 | $11.65M derived: sum of 2 quarters · filed 2023-11-07 | $18.43M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $5.59M 10-Q · filed 2023-08-07 | $12.37M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $6.78M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |